Darvadstrocel: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 23: | Line 23: | ||
[[Category:Stem cell therapy]] | [[Category:Stem cell therapy]] | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 08:31, 17 March 2025
Darvadstrocel is a stem cell therapy used in the treatment of perianal fistulas in patients with Crohn's disease. It is a product of Takeda Pharmaceutical Company, a Japanese multinational pharmaceutical and biopharmaceutical company.
Etymology[edit]
The term "Darvadstrocel" is a coined name, with no known etymology.
Medical Use[edit]
Darvadstrocel is used in the treatment of perianal fistulas in patients with Crohn's disease. Perianal fistulas are a common complication of Crohn's disease, a type of inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract. Darvadstrocel is a stem cell therapy, which involves the use of stem cells to replace or repair damaged cells in the body.
Mechanism of Action[edit]
The exact mechanism of action of Darvadstrocel is not fully understood. However, it is believed to work by promoting the healing of fistulas through the action of stem cells. These cells have the ability to differentiate into various types of cells, which can then replace the damaged cells in the fistula.
Side Effects[edit]
As with any medication, Darvadstrocel can cause side effects. The most common side effects include pain at the injection site, anal abscess, and fever. If these side effects persist or worsen, patients are advised to seek medical attention.
